Differential induction of antibody-dependent cellular cytotoxicity (ADCC) against human EGFR-expressing NSCLC cell lines by necitumumab, cetuximab, and panitumumab.

• DOI: 10.1200/jco.2011.29.15_suppl.e21075
• Publication Date: 2017-02-23T18:58:03Z
• Authors: D. Patel; B. Saxena; Q. Zhou; W. Walton; R. Srikakulum; R. Manteiga; J. Haurum; J. R. Tonra; X. Kang
• Keywords: Panitumumab; Jurkat cells; EGFR Inhibitors

e21075 Background: Necitumumab, cetuximab and panitumumab are monoclonal antibodies specific for human epidermal growth factor receptor (EGFR). They act as functional antagonists by blocking ligand binding (EGF TGFa) to EGFR inhibit activation downstream signaling in tumor cells. Necitumumab IgG1 molecules is an IgG2 molecule. Methods: In the present study, we analyzed of all three EGFR, Fc receptors C1q. We also examined ability elicit antibody-dependent cellular cytotoxicity (ADCC) vitro using non-small cell lung cancer (NSCLC) cells expressing various levels EGFR. Fc-receptor C1q activity was evaluated ELISA. ADCC with a reporter gene based assay Jurkat or peripheral blood mononuclear (PBMC) from normal donors effector Results: exhibited similar FcgRIa, FcgRIIa, FcgRIIIa C1q, whereas no observed panitumumab. induced potent against NSCLC at concentration low 1.0 nM. Interestingly, extent necitumumab correlated level expression on surface. Panitumumab did not cells, even though that cetuximab. Conclusions: Both cetuximab, but panitumumab, target EGFR-expressing ADCC, magnitude correlates level. studies suggest relative abilities fix complement will parallel results ADCC.